BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 872 filers reported holding BAXTER INTL INC in Q2 2016. The put-call ratio across all filers is 0.49 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $4,948,000 | -4.0% | 76,075 | -4.6% | 0.14% | +1.4% |
| Q4 2017 | $5,152,000 | -10.3% | 79,706 | -12.9% | 0.14% | -2.8% |
| Q3 2017 | $5,744,000 | +1.3% | 91,541 | -2.3% | 0.14% | +2.1% |
| Q2 2017 | $5,670,000 | +1.3% | 93,649 | -13.2% | 0.14% | +14.5% |
| Q1 2017 | $5,598,000 | +11.4% | 107,940 | -4.7% | 0.12% | +10.7% |
| Q4 2016 | $5,024,000 | -15.5% | 113,309 | -9.3% | 0.11% | -9.7% |
| Q3 2016 | $5,949,000 | -8.0% | 124,987 | -12.6% | 0.12% | -9.5% |
| Q2 2016 | $6,464,000 | +18.0% | 142,953 | +7.2% | 0.14% | +9.6% |
| Q1 2016 | $5,480,000 | +17.1% | 133,393 | +8.8% | 0.12% | +7.8% |
| Q4 2015 | $4,678,000 | +13.7% | 122,610 | -2.1% | 0.12% | +10.5% |
| Q3 2015 | $4,114,000 | -51.3% | 125,234 | +3.7% | 0.10% | -49.3% |
| Q2 2015 | $8,449,000 | -5.5% | 120,823 | -7.4% | 0.21% | +2.5% |
| Q1 2015 | $8,938,000 | -4.6% | 130,482 | +2.1% | 0.20% | -6.5% |
| Q4 2014 | $9,365,000 | -1.7% | 127,776 | -3.7% | 0.22% | -2.3% |
| Q3 2014 | $9,526,000 | -4.6% | 132,733 | -3.9% | 0.22% | -1.8% |
| Q2 2014 | $9,981,000 | -4.6% | 138,050 | -3.0% | 0.22% | -5.5% |
| Q1 2014 | $10,467,000 | +6.5% | 142,257 | +0.7% | 0.24% | +4.4% |
| Q4 2013 | $9,825,000 | +3.7% | 141,270 | -2.1% | 0.23% | -4.2% |
| Q3 2013 | $9,479,000 | -9.1% | 144,306 | -4.2% | 0.24% | -8.8% |
| Q2 2013 | $10,432,000 | – | 150,595 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |